Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET

Company Participants

Donald Notman - CFO

Antony Mattessich - President and CEO

Rabia Ozden - CMO

Steve Meyers - SVP, Commercial

Peter Kaiser - Chief Medical Advisor, Retina

Conference Call Participants

Jon Wolleben - JMP

Yi Chen - H.C. Wainwright

Operator

Good day. Thank you for standing by. Welcome to the Third Quarter 2023 Ocular Therapeutix Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Donald Notman, CFO. Please go ahead.

Donald Notman

Thank you, operator. Good afternoon everyone and thank you for joining us on our third quarter 2023 financial results and business update conference call. This afternoon, after the close, we issued a press release providing an update on the company's product development programs and details of the company's financial results for the third quarter ended September 30th, 2023. The press release can be accessed on the Investors' portion of our website at investors.ocutx.com.

Leading the call today will be Antony Mattessich, our President and Chief Executive Officer, who will provide an update on our pipeline developments and the commercial progress of DEXTENZA. Also speaking on the call today will be Dr. Rabia Ozden, our Chief Medical Officer; and Steve Meyers, our Senior Vice President, Commercial; and Dr. Peter Kaiser, Chief Medical Advisor, Retina. Unfortunately, Peter will now be available during the Q&A. Following their remarks, I will provide an overview of the financial highlights for the quarter, before turning the call back over to Antony for his summary and questions.

As a reminder, on today's call, certain statements we will be making may be considered forward-looking for the purposes of the Private Securities Litigation Reform Act of 1995.

In particular, any statements regarding our anticipated net product revenues and our regulatory and product development plans, as well as our research activities are forward-looking statements.

These statements are subject to a variety of risks and uncertainties that may cause actual results to differ from those forecasted, including those risks described in our Form 10-Q filed this afternoon with the SEC and our most recent annual report on Form 10-K filed March 6th, 2023.

I will now turn the call over to Antony.